Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Research

Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group

Authors: Seok Jin Kim, Hyun Ae Jung, Shih-Sung Chuang, Huangming Hong, Cheng-Cheng Guo, Junning Cao, Xiao-Nan Hong, Ritsuro Suzuki, Hye Jin Kang, Jong Ho Won, Wee-Joo Chng, Yok-Lam Kwong, Cheolwon Suh, Yu-Qin Song, Jun Zhu, Kevin Tay, Soon Thye Lim, Junji Suzumiya, Tong-Yu Lin, Won Seog Kim

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

Background

The gastrointestinal (GI) tract is one of the most common extranasal sites in extranodal NK/T-cell lymphoma (ENKTL). However, data regarding ENKTL involving the GI tract are relatively scarce. Thus, we performed a multicenter, multinational retrospective study to analyze clinical features and treatment outcomes of ENKTL involving the GI tract.

Patients and methods

Patients with ENKTL involving the GI tract diagnosed in twelve participating centers between 1991 and 2012 were retrospectively analyzed from five Asian countries.

Results

The analysis of 81 patients with ENKTL involving the GI tract revealed that more than 60% of patients presented as advanced disease with B symptoms. 55 patients (68%) had GI manifestations including abdominal pain (n = 26, 32%), GI tract bleeding (n = 17, 21%) and bowel perforation (n = 12, 15%). The most common GI site was the small intestine, including the jejunum and ileum (n = 57, 70.3%). There were 34 patients (42%) who received systemic chemotherapy while 33 patients (41%) underwent surgery plus chemotherapy. However, 35 patients (43%) died due to disease progression, and treatment-related mortality including sepsis occurred in 17 patients (21%). Thus, the median overall survival was 7.8 months (95% Confidence interval: 3.9 – 11.7 months). Patients who could undergo surgery plus chemotherapy showed a trend of better survival than those treated with chemotherapy alone.

Conclusion

Overall, the data indicated that ENKTL involving the GI tract has a dismal prognosis despite active treatment including chemotherapy and surgery. Thus, more effective treatment strategies are required for this disease entity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kim SJ, Kim WS: Treatment of localized extranodal NK/T cell lymphoma, nasal type. Int J Hematol. 2010, 92: 690-696. 10.1007/s12185-010-0720-8.CrossRefPubMed Kim SJ, Kim WS: Treatment of localized extranodal NK/T cell lymphoma, nasal type. Int J Hematol. 2010, 92: 690-696. 10.1007/s12185-010-0720-8.CrossRefPubMed
2.
go back to reference Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, Huh JR, Yoon DH, Oh SY, Kim JS, Lee SI, Park KW, Hsieh PP, Nakamura S, Yoshino T, Ito K, Nagatani T, Oshimi K, Suzuki R, Kim WS: Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Ann Oncol. 2012, 23: 2703-2707. 10.1093/annonc/mds096.CrossRefPubMed Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, Huh JR, Yoon DH, Oh SY, Kim JS, Lee SI, Park KW, Hsieh PP, Nakamura S, Yoshino T, Ito K, Nagatani T, Oshimi K, Suzuki R, Kim WS: Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Ann Oncol. 2012, 23: 2703-2707. 10.1093/annonc/mds096.CrossRefPubMed
3.
go back to reference Chim CS, Au WY, Shek TW, Ho J, Choy C, Ma SK, Tung HM, Liang R, Kwong YL: Primary CD56 positive lymphomas of the gastrointestinal tract. Cancer. 2001, 91: 525-533. 10.1002/1097-0142(20010201)91:3<525::AID-CNCR1030>3.0.CO;2-U.CrossRefPubMed Chim CS, Au WY, Shek TW, Ho J, Choy C, Ma SK, Tung HM, Liang R, Kwong YL: Primary CD56 positive lymphomas of the gastrointestinal tract. Cancer. 2001, 91: 525-533. 10.1002/1097-0142(20010201)91:3<525::AID-CNCR1030>3.0.CO;2-U.CrossRefPubMed
4.
go back to reference D’Amore F, Brincker H, Gronbaek K, Thorling K, Pedersen M, Jensen MK, Andersen E, Pedersen NT, Mortensen LS: Non-Hodgkin’s lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma study group. J Clin Oncol. 1994, 12: 1673-1684.PubMed D’Amore F, Brincker H, Gronbaek K, Thorling K, Pedersen M, Jensen MK, Andersen E, Pedersen NT, Mortensen LS: Non-Hodgkin’s lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma study group. J Clin Oncol. 1994, 12: 1673-1684.PubMed
5.
go back to reference Ko YH, Kim CW, Park CS, Jang HK, Lee SS, Kim SH, Ree HJ, Lee JD, Kim SW, Huh JR: REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer. 1998, 83: 806-812.CrossRefPubMed Ko YH, Kim CW, Park CS, Jang HK, Lee SS, Kim SH, Ree HJ, Lee JD, Kim SW, Huh JR: REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer. 1998, 83: 806-812.CrossRefPubMed
6.
go back to reference Kim SJ, Choi CW, Mun YC, Oh SY, Kang HJ, Lee SI, Won JH, Kim MK, Kwon JH, Kim JS, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Lee JH, Oh S, Park KW, Suh C, Kim WS: Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). BMC Cancer. 2011, 11: 321-10.1186/1471-2407-11-321.PubMedCentralCrossRefPubMed Kim SJ, Choi CW, Mun YC, Oh SY, Kang HJ, Lee SI, Won JH, Kim MK, Kwon JH, Kim JS, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Lee JH, Oh S, Park KW, Suh C, Kim WS: Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). BMC Cancer. 2011, 11: 321-10.1186/1471-2407-11-321.PubMedCentralCrossRefPubMed
7.
go back to reference Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS: Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood. 2011, 117: 1958-1965. 10.1182/blood-2010-06-288480.CrossRefPubMed Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS: Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood. 2011, 117: 1958-1965. 10.1182/blood-2010-06-288480.CrossRefPubMed
8.
go back to reference Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS: Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006, 24: 612-618. 10.1200/JCO.2005.04.1384.CrossRefPubMed Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS: Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006, 24: 612-618. 10.1200/JCO.2005.04.1384.CrossRefPubMed
9.
go back to reference Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996, 17: 343-346. 10.1016/0197-2456(96)00075-X.CrossRefPubMed Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996, 17: 343-346. 10.1016/0197-2456(96)00075-X.CrossRefPubMed
11.
go back to reference Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R: Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011, 29: 4410-4416. 10.1200/JCO.2011.35.6287.CrossRefPubMed Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R: Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011, 29: 4410-4416. 10.1200/JCO.2011.35.6287.CrossRefPubMed
12.
go back to reference Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS: SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012, 120: 2973-2980. 10.1182/blood-2012-05-431460.CrossRefPubMed Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS: SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012, 120: 2973-2980. 10.1182/blood-2012-05-431460.CrossRefPubMed
Metadata
Title
Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group
Authors
Seok Jin Kim
Hyun Ae Jung
Shih-Sung Chuang
Huangming Hong
Cheng-Cheng Guo
Junning Cao
Xiao-Nan Hong
Ritsuro Suzuki
Hye Jin Kang
Jong Ho Won
Wee-Joo Chng
Yok-Lam Kwong
Cheolwon Suh
Yu-Qin Song
Jun Zhu
Kevin Tay
Soon Thye Lim
Junji Suzumiya
Tong-Yu Lin
Won Seog Kim
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-86

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine